Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NCT07315113

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients

Nuvectis Pharma, Inc.18 participantsStarted Dec 2025

Boston, Massachusetts, United States • Houston, Texas, United States • Fairfax, Virginia, United States

Data from ClinicalTrials.govTerms

Filters

Filters

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer